Table 3

 Insulin sensitising agents in the treatment non-alcoholic fatty liver disease

AuthorInterventionNumberStudy typeComparisonDuration (months)ALTHistology
SteatosisInflammationFibrosis
*Determined by magnetic resonance spectroscopy; †improvement seen in zone 3 fibrosis but not overall fibrosis score.
Magalotti55Metformin11Pilot trialBaseline6ImprovedNANANA
Schwimmer56Metformin10Pilot trialBaseline6ImprovedImproved*NANA
Nair57Metformin15Pilot trialBaseline12No changeNo changeNo changeNo change
Marchesini54Metformin14Pilot trialBaseline4ImprovedNANANA
Bugianesis58Metformin110Open label, randomisedVitamin E or diet12ImprovedNANANA
Promrat67Pioglitazone18Pilot trialBaseline11ImprovedImprovedImprovedImproved
Bajaj93Pioglitazone11Pilot trialBaseline4NAImproved*NANA
Shadid94Pioglitazone5Pilot trialBaseline4ImprovedNANANA
Neuschwander-Tetri66Rosiglitazone30Pilot trialBaseline11ImprovedImprovedImprovedNo change†
Sanyal68Pioglitazone + vitamin E20Open label, randomisedVitamin E6No differenceNo differenceImprovedNo difference